BC Innovations | Dec 12, 2019
Distillery Therapeutics

Combined inhibition of CDK12 and CDK13 for TNBC

DISEASE CATEGORY: Cancer INDICATION: Breast cancer A Moffitt Cancer Center and Research Institute team showed that dual inhibition of CDK12 and CDK13 could treat triple-negative breast cancer (TNBC). In four human TNBC cell lines, an...
BC Extra | Dec 4, 2019
Company News

Dec. 3 Company Quick Takes: Brii adds neuroscience focus; plus Immunomedics, Hanmi-Rapt, Luye-Boan and Cara

Brii steps into neuroscience  Cross-border biotech Brii Biosciences said it will begin developing neuroscience programs as its second therapeutic area of interest, adding to its original focus on infectious diseases. The Beijing, China, and Durham,...
BC Innovations | Aug 14, 2019
Distillery Therapeutics

Phage-linked chemo could help treat colorectal cancer

DISEASE CATEGORY: Cancer INDICATION: Colorectal cancer A phage-directed nanoparticle could enable the targeted delivery of chemotherapy and eliminate oncogenic bacteria to treat colorectal cancer (CRC). To generate the therapy, a team from Wuhan University chemically...
BC Innovations | Aug 1, 2019
Distillery Therapeutics

Tumor-penetrating camptothecin conjugate for liver, pancreatic cancers

DISEASE CATEGORY: Cancer INDICATION: Liver cancer; pancreatic cancer A team led by ZenCapsule Inc. scientific co-founder Zhen Gu showed that a tumor-penetrating polymeric camptothecin conjugate could treat liver and pancreatic cancers. The conjugate consists of...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BC Extra | Jun 17, 2019
Company News

Array takeout buoys biotechs, strengthens Pfizer in targeted oncology

Public biotechs got a boost Monday on the strength of Pfizer's $11.4 billion buyout of Array, signaling that continued M&A interest in the sector can help reverse the loss in momentum that has led to...
BC Extra | May 21, 2019
Clinical News

May 21 Clinical Quick Takes: Array gains on colorectal cancer plans; plus Tocagen, Promedior

Array planning submissions for colorectal cancer triplet  Array BioPharma Inc. (NASDAQ:ARRY) gained $4.81 (23%) to $25.77 on Tuesday after interim data from the Phase III BEACON CRC trial to treat BRAF V600E-mutant metastatic colorectal cancer...
BC Week In Review | Mar 1, 2019
Clinical News

FDA approves Lonsurf for gastric cancer

Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan) said FDA approved Lonsurf trifluridine/tipiracil for adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine,...
BC Week In Review | Jan 25, 2019
Clinical News

FDA delays approval of Immunomedics' ADC for triple-negative breast cancer

Immunomedics Inc. (NASDAQ:IMMU) said FDA issued a complete response letter for its BLA for sacituzumab govitecan (IMMU-132) to treat metastatic triple-negative breast cancer in a third-line setting. The company was seeking accelerated approval of the...
BC Extra | Jan 18, 2019
Company News

FDA delays approval of Immunomedics' ADC for triple-negative breast cancer

Immunomedics Inc. (NASDAQ:IMMU) said FDA issued a complete response letter for its BLA for sacituzumab govitecan (IMMU-132) to treat metastatic triple-negative breast cancer in a third-line setting. The company was seeking accelerated approval of the...
Items per page:
1 - 10 of 778